1427 related articles for article (PubMed ID: 31200752)
1. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
2. p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors.
Grassilli E; Cerrito MG; Bonomo S; Giovannoni R; Conconi D; Lavitrano M
Front Cell Dev Biol; 2021; 9():690365. PubMed ID: 34164404
[TBL] [Abstract][Full Text] [Related]
3. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
Lavitrano M; Ianzano L; Bonomo S; Cialdella A; Cerrito MG; Pisano F; Missaglia C; Giovannoni R; Romano G; McLean CM; Voest EE; D'Amato F; Noli B; Ferri GL; Agostini M; Pucciarelli S; Helin K; Leone BE; Canzonieri V; Grassilli E
J Pathol; 2020 Feb; 250(2):134-147. PubMed ID: 31518438
[TBL] [Abstract][Full Text] [Related]
4. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
5. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
6. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
8. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
10. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
[TBL] [Abstract][Full Text] [Related]
12. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
Chen YM
J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
[TBL] [Abstract][Full Text] [Related]
13. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
14. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
16. USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Zhang H; Han B; Lu H; Zhao Y; Chen X; Meng Q; Cao M; Cai L; Hu J
Cancer Lett; 2018 Oct; 433():186-198. PubMed ID: 29981430
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Jiang Y; Yuan Q; Fang Q
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
20. Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers.
Bagnyukova T; Egleston BL; Pavlov VA; Serebriiskii IG; Golemis EA; Borghaei H
Cancer Res Commun; 2024 May; 4(5):1227-1239. PubMed ID: 38639476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]